

# The 4<sup>th</sup> WBMT WORKSHOP

15-16 JANUARY 2017


RIYADH, SAUDI ARABIA

## ALGERIA ACTIVITY REPORT

HEMATOLOGY AND CELL THERAPY DEPARTMENT/ EHU<sup>1st</sup>

NOVEMBER, ORAN, ALGERIA

M.A BEKADJA





# ALGERIA ACTIVITY REPORT

---

**NO CONFLICT OF INTEREST**

# ALGERIA ACTIVITY REPORT



# ALGERIA ACTIVITY REPORT

---

- ✧ Total population (2016) = **40.4 millions** and half of which is under 30 years.
- ✧ Per capita income= **4132.6 \$**
- ✧ Gross National Income per capita (\$ PPP, 2013) = **12**
- ✧ Life expectancy at birth M / F (year, 2015) = **74/78**

# ALGERIA ACTIVITY REPORT

---

- ✧ In Algeria, Health-care insurance covered, 90% of the population. **Health care is free** and it is supported by the Ministry of Health.
- ✧ The annual per capita medical expenditure is (2014) **\$932**
- ✧ Total annual expenditure on health as **7.2%** of GDP (2014)

# ALGERIA ACTIVITY REPORT



## CPMC Algiers:



Total number of transplants (2016):

**180**

## Number of transplants by category:

- Re-transplants:
- Unrelated donor transplants:
- **Related donor transplants:**
- Cord blood transplants:

**90%**

Indications for autologous transplant (52):

Multiple Myeloma (**60%**), Lymphoma (**40%**)

**29%**

Indications for allogeneic transplant (128):

AL( **80%**), Aplastic Anemia, Myelodysplastic syndrome, others (**20%** )

**71%**

## EHU 1st November Oran:

Total number of transplants in our center (2016): **90**

### Number of transplants by category:

- Re-transplants: **02**
- Unrelated donor transplants: **00**
- **Related donor transplants: 21**
- **Autologous transplants: 69**
- Cord blood transplants: **00**



**Indications for autologous transplant (69):**

Multiple Myeloma (), Lymphoma ()

**77%**

**Indications for allogeneic transplant (21):**

AL (**90%**), Aplastic Anemia, Myelodysplastic syndrome (**10%**)

**23%**



## EHU 1st November-Oran



**Total autologous transplantation with non cryopreserved HSC (2009-2016)= 352**

- ① MM= 240
- ② HL= 82
- ③ NHL= 30

## EHU 1st November-Oran



	H0	H24	H48	H72
<b>Viability (median)</b>	<b>98%</b>	<b>97.6%</b>	<b>96%</b>	<b>95%</b>
<b>Viability (range)</b>	<b>97.4 – 100</b>	<b>92.4 – 99.4</b>	<b>91.6-98</b>	<b>91-96</b>

	DAY : 0 (n=25)	DAY : 6 (n=25)
<b>Viability ( % ) Per Bag</b>	93,77 ( 70-100 )	<b>82,18 ( 54,24 – 94 )</b>
<b>MNC ( % ) Per Bag</b>	51,24 ( 25,85 – 71,21 )	57,05 ( 39,71 – 75 )
<b>CD34+ ( % ) Per Bag</b>	0,73 ( 0,16 – 1,94 )	0,34 ( 0,19 – 0,54 )

## EHU 1st November-Oran



Median	MM (n=240)	LYMPHOMA (n=112)
CD34 <sup>+</sup> x 10 <sup>6</sup> cells/kg	5,7 (2,3-13,2)	3,66 (3,3-9,7)
Duration of neutropenia	10 (6-17)	13 (9-14)
Duration of thrombocytopenia	13 (9-24)	14 (10-37)
Duration of hospitalization	17 (12-30)	21 (15-37)
Transplant related mortality	1,3%	2%

## EHU 1st November-Oran



**We conclude:**

- Autologous transplant with non cryopreserved HSC is a simple, effective and safe method.**
- The cryopreservation is not necessary in our work conditions in developing countries.**

## In summary for the two transplant centers:

The predominant types of transplantation performed are:

① identical sibling (**41%**)

① haploidentical (**13%**)

② autologous (**46%**)

**(54%)**

③ Approximately the total number of transplantation per year (2016) was: **270**

## Indications for autologous transplant:

- ① Multiple Myeloma **(65%)**
  - ② Hodgkin's disease **(19%)**
  - ① non-Hodgkin 's lymphoma **(16%)**
- (35%)**

## Indications for allogeneic transplant:

- ① AML/MDS **(73%)**
- ② ALL **(19%)**
- ③ Aplastic Anemia **(08%)**
- ④ Thalassemia, Fanconi

- ① The cumulative incidence of acute GVHD are 45% and of II–IV aGVHD are 32% in identical sibling transplant.
  
- ② The cumulative incidence of cGVHD are 38% and severe cGVH 9%.



# ALGERIA ACTIVITY REPORT

---

## The particularity in Algeria:

The majority of recipients and donors are CMV positive.





Allo-SCT in Algeria costs around US\$ **15 000–20 000** and autologous SCT costs around US\$ **10 000**, and it is totally sponsored by medical insurance and the Ministry of Health.

## National society:

No, but there is an Algerian bone marrow transplant group

## Data report to international society:

EBMT (Alger CIC: Team 703:1; Oran CIC: Team 993:1)

EMBMT: Yes

SFGM-TC: Yes

National recipient registry

No

Cord blood bank

Yes

Donor registry

No

Quality management

No

## The projects are:

- ① Achieving the autograft in all University Hospitals **with non cryopreserved HSC.**
- ② Achieving a center allograft in the **east of the country.**
- ③ The development of **bone marrow transplantation in children.**

## Conclusion :

-Currently in Algeria, the number of transplantation is **insufficient** and the development of new transplant centers is essential.


-In the future, we hope to implement the National Society of Bone Marrow transplant and the National recipient registry and Donor registry.

# ORAN EHU TEAM



THANK YOU VERY MUCH





# Algeria